Ankylosing spondylitis (AS) is a chronic in ammatory disease of the axial spine that manifests with various clinical signs and symptoms; however, the quantitative detection of in ammation in AS remains a drawback in clinical settings. We aimed to investigate the feasibility of using a speci c P2X7R-targeting 18 F-labeled tracer [ 18 F]GSK1482160 for positron emission tomography (PET) imaging and the quanti cation of AS.
MethodsThe radioligand [ 18 F]GSK1482160 was obtained based on nucleophilic aromatic radio uorination with [ 18 F] uoride. Dynamic [ 18 F]GSK1482160 and [ 18 F]FDG micro-PET/CT imaging were performed on AS mouse models and age-matched controls. Tracer kinetics modeling was performed using Logan graphical arterial input function analysis and Patlak models to quantify the in vivo expression of P2X7R and the in ux rate of [ 18 F]FDG, respectively. The post-PET tissues were collected for hematoxylin-eosin, immunohistochemical (IHC), and immuno uorescence (IF) staining.
ResultsThe decay-corrected radiochemical yield (RCY) of [ 18 F]GSK1482160 was 20-30%; radiochemical purity, ≥ 98%; and molar activity, 55-85 GBq/µmol. [ 18 F]GSK1482160 PET/CT imaging revealed that the speci c binding in the ankle joint and sacroiliac joint (SIJ) of the AS group (BP ND ankle = 13.75 ± 2.20, BP ND SIJ = 15.87 ± 3.90) were signi cantly higher than that of the control group (BP ND ankle = 0.14 ± 0.08, BP ND SIJ = 0.75 ± 0.48). In contrast, in [ 18 F]FDG imaging, there was no signi cant difference in the uptake in the ankle joint and SIJ between the two groups. IHC and IF staining revealed that the overexpression of P2X7R was colocalized with activated macrophages from the ankle synovium and spinal endplate in mice with AS, indicating that quanti cation of P2X7R may contribute to the pathogenesis of in ammation in human AS.
ConclusionThis study developed a novel P2X7R-targeting PET tracer [ 18 F]GSK1482160 to detect the expression of P2X7R in AS mouse models and provided a powerful non-invasive PET imaging and quanti cation for AS.